Yupelri for Chronic Obstructive Pulmonary Disease

News
Article

Yupelri Product Image

Yupelri (revefenacin, Mylan®)

Indications: Patients with chronic obstructive pulmonary disease

Dosage: One 175 mcg vial (3 mL) once daily.

Contraindications: hypersensitivity to revefenacin or any component of this product.

Click here for more prescribing information

© 2024 MJH Life Sciences

All rights reserved.